Bangladesh - English - DGDA (Directorate General of Drug Administration)

jenphar bangladesh ltd. - cefuroxime + clavulanic acid - tablet - 500 mg + 125 mg

India - English - Central Drugs Standard Control Organization

unisearch hc. - ofloxacin,ornidazole - oz - 250,500;mg - 10

India - English - Central Drugs Standard Control Organization

unisearch hc. - ofloxacin - tab - 200mg - 10

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin -

United States - English - NLM (National Library of Medicine)

schering plough corporation - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3 )] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4 )]. avelox is indicated in adult patients for the treatment of complicated skin and ski

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4)]. avelox is indicated in adult patients for the treatment of complicated skin and skin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - ciprofloxacin lactate - infusion - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - ciprofloxacin lactate - infusion - 2mg/1ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd - infusion - each 5,0 ml solution contains ciprofloxacin lactate equivalent to ciprofloxacin 2,0 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ciprofloxacin 2 mg/ml - solution for infusion - ciprofloxacin